Cite
Camps C, Sarries C, Roig B, et al. Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin Lung Cancer. 2003;4(4):237-41doi: 10.3816/clc.2003.n.004.
Camps, C., Sarries, C., Roig, B., Sanchez, J. J., Queralt, C., Sancho, E., Martinez, N., Tarón, M., & Rosell, R. (2003). Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clinical lung cancer, 4(4), 237-41. https://doi.org/10.3816/clc.2003.n.004
Camps, Carlos, et al. "Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients." Clinical lung cancer vol. 4,4 (2003): 237-41. doi: https://doi.org/10.3816/clc.2003.n.004
Camps C, Sarries C, Roig B, Sanchez JJ, Queralt C, Sancho E, Martinez N, Tarón M, Rosell R. Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin Lung Cancer. 2003 Jan;4(4):237-41. doi: 10.3816/clc.2003.n.004. PMID: 14624713.
Copy
Download .nbib